Jon Akutagawa, PhD
Postdoctoral Scholar
Medicine
School of Medicine

Publications (10)

Top publication keywords:
Leukemia, ExperimentalReceptor, Platelet-Derived Growth Factor betaMitogen-Activated Protein Kinase KinasesHematopoiesis, ExtramedullaryProto-Oncogene Proteins p21(ras)Precursor B-Cell Lymphoblastic Leukemia-LymphomaSmall Molecule LibrariesProto-Oncogene Proteins c-bcl-2DiphenylamineDiploidyBenzamidesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNeoplasm Regression, SpontaneousPhospholipase C gammaLeukemia, Myelomonocytic, Juvenile

• A novel splice site variant in DEGS1 leads to aberrant splicing and loss of DEGS1 enzyme activity, a VUS resolved.
  medRxiv : the preprint server for health sciences 2025 Beale HC, Tse V, Lee JY, Akutagawa J, Mavura Y, Saint-John B, Cheney A, Mulligan DR, Chacaltana G, Gutierrez M, Tenney J, Shieh JT, Martin PM, Yip T, Hodoglugil U, Fay AJ, Brooks AN, Van Ziffle J, …
• The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.
  Haematologica 2021 Tran TH, Nguyen JV, Stecula A, Akutagawa J, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML
• Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.
  Cancer research 2019 Diaz-Flores E, Comeaux EQ, Kim KL, Melnik E, Beckman K, Davis KL, Wu K, Akutagawa J, Bridges O, Marino R, Wohlfeil M, Braun BS, Mullighan CG, Loh ML
• Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.
  Nature communications 2017 Stieglitz E, Mazor T, Olshen AB, Geng H, Gelston LC, Akutagawa J, Lipka DB, Plass C, Flotho C, Chehab FF, Braun BS, Costello JF, Loh ML
• Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
  The Journal of clinical investigation 2016 Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K

Show all (5 more) Hide

• Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
  Blood 2014 Stieglitz E, Troup CB, Gelston LC, Haliburton J, Chow ED, Yu KB, Akutagawa J, Taylor-Weiner AN, Liu YL, Wang YD, Beckman K, Emanuel PD, Braun BS, Abate A, Gerbing RB, Alonzo TA, Loh ML
• PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
  Science signaling 2013 Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K
• Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
  The Journal of clinical investigation 2012 Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K
• A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
  Science translational medicine 2011 Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS
• Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.
  Bioconjugate chemistry 2008 Stephan JP, Chan P, Lee C, Nelson C, Elliott JM, Bechtel C, Raab H, Xie D, Akutagawa J, Baudys J, Saad O, Prabhu S, Wong WL, Vandlen R, Jacobson F, Ebens A